Study of HER2 Directed Dendritic Cell (DC1) Vaccine + Weekly Paclitaxel, Trastuzumab & Pertuzumab

Study of HER2 Directed Dendritic Cell (DC1) Vaccine + Weekly Paclitaxel, Trastuzumab & Pertuzumab
Condition:   HER2-positive Breast Cancer
Interventions:   Biological: HER-2 pulsed DC1;   Drug: Trastuzumab;   Drug: Pertuzumab;   Drug: Paclitaxel;   Procedure: Resection surgery
Sponsors:   H. Lee Moffitt Cancer Center and Research Institute;   ImmunoRestoration
**RECRUITING NOW**

Source: View full study details on ClinicalTrials.gov

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. By listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.

April 14, 2022Comments OffClinicalTrials.gov | Oncology Clinical Trials | Oncology Studies | US National Library of Medicine
Comments